一种基于模型的变异特征稳健估计框架
A flexible model-based framework for robust estimation of mutational signatures
摘要:
癌症中的体细胞突变可以被视为几种突变特征的混合分布,其可以使用非负矩阵因子分解(NMF)来推断。突变特征先前已经使用简单的单核苷酸相互作用模型或一般的三核苷酸相互作用模型参数化。我们描述了一个灵活的和新颖的框架,用于识别生物学上合理的突变签名参数化,特别是用于估计双核苷酸相互作用模型。估计过程是基于期望最大化(EM)算法和回归的对数线性准泊松模型。我们表明,双核苷酸相互作用的签名是统计稳定的,足够复杂,以适应突变模式。二核苷酸相互作用特征通常在适当拟合数据和避免过度拟合之间取得适当的平衡。它们提供了更好的数据拟合,并且在生物学上比单核苷酸相互作用特征更合理,并且参数化比富含参数的三核苷酸相互作用特征更稳定。我们说明了我们的框架上的三个数据集的癌症患者的体细胞突变计数。
英文摘要:
Somatic mutations in cancer can be viewed as a mixture distribution of several mutational signatures, which can be inferred using non-negative matrix factorization (NMF). Mutational signatures have previously been parametrized using either simple mono-nucleotide interaction models or general tri-nucleotide interaction models. We describe a flexible and novel framework for identifying biologically plausible parametrizations of mutational signatures, and in particular for estimating di-nucleotide interaction models. The estimation procedure is based on the expectation--maximization (EM) algorithm and regression in the log-linear quasi--Poisson model. We show that di-nucleotide interaction signatures are statistically stable and sufficiently complex to fit the mutational patterns. Di-nucleotide interaction signatures often strike the right balance between appropriately fitting the data and avoiding over-fitting. They provide a better fit to data and are biologically more plausible than mono-nucleotide interaction signatures, and the parametrization is more stable than the parameter-rich tri-nucleotide interaction signatures. We illustrate our framework on three data sets of somatic mutation counts from cancer patients.
机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。